Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas
Dourado, Mauricio Rocha; Machado, Renato Assis; Ribeiro Paranaíba3, Lívia Máris; González-Arriagada, Wilfredo Alejandro; da Silva, Sabrina Daniela; Sawazaki-Calone, Íris; Graner, Edgard; Salo, Tuula; Coletta, Ricardo D. (2021-02-22)
Dourado, MR, Machado, RA, Paranaíba, LMR, et al. Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas. Oral Dis. 2022; 28: 1085–1093. https://doi.org/10.1111/odi.13809
© 2021 Wiley Periodicals LLC. This is the peer reviewed version of the following article: Dourado, MR, Machado, RA, Paranaíba, LMR, et al. Trophoblast cell surface antigen 2 expression predicts outcome in oral squamous cell carcinomas. Oral Dis. 2021; 00: 1– 9, which has been published in final form at https://doi.org/10.1111/odi.13809. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.
https://rightsstatements.org/vocab/InC/1.0/
https://urn.fi/URN:NBN:fi-fe2021062840256
Tiivistelmä
Abstract
Background: Trophoblast cell surface antigen 2 (TROP2) has unclear clinical role in oral squamous cell carcinomas (OSCC). Here, we investigated the association of TROP2 immunoexpression with clinicopathological parameters and survival of OSCC patients.
Subjects and Methods: Cancer-specific survival (CSS) and disease-free survival (DFS) were assessed in a cohort composed of 266 OSCC. An independent cohort with 88 OSCC samples matched with the normal oral tissue, as well as 17 metastatic lymph nodes, was used for validation.
Results: Multivariate analysis showed TROP2 as an independent marker of favorable prognosis for both CSS (HR: 0.60, 95% CI: 0.40–0.90, p = .01) and DFS (HR: 0.57, 95% CI: 0.36–0.89, p = .01). Furthermore, TROP2 protein expression was significantly higher in morphologically normal tissues compared to primary tumors (p < .0001) and lymph node metastases (p = .001), and it was significantly associated with CSS (HR: 0.26, 95% CI: 0.09–0.74, p = .008) in the validation cohort. A pooled mRNA analysis performed on the Oncomine™ database confirmed the underexpression in OSCC compared with normal tissues (p = .014).
Conclusions: In summary, our results point to a favorable prognostic significance of TROP2 overexpression in a large cohort of oral cancer patients, suggesting it as an attractive clinical marker.
Kokoelmat
- Avoin saatavuus [38697]